A smartphone- and wearable-based biomarker for the estimation of unipolar depression severity

• Published in: Scientific reports Vol. 13; no. 1; p. 18844
• Main Authors: Zhuparris, Ahnjili, Maleki, Ghobad, van Londen, Liesbeth, Koopmans, Ingrid, Aalten, Vincent, Yocarini, Iris E., Exadaktylos, Vasileios, van Hemert, Albert, Cohen, Adam, Gal, Pim, Doll, Robert-Jan, Groeneveld, Geert Jan, Jacobs, Gabriël, Kraaij, Wessel
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.11.2023; Nature Publishing Group; Nature Portfolio
• Subjects: 692/308/2779; 692/308/409; 692/308/53; 692/308/575; 692/53/2421; 692/53/2422; 692/53/2423; Biomarkers; Clinical trials; Drug development; Emotions; Humanities and Social Sciences; Mental depression; multidisciplinary; Science; Science (multidisciplinary); Self report; Smartphones
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-023-46075-2

Drug development for mood disorders can greatly benefit from the development of robust, reliable, and objective biomarkers. The incorporation of smartphones and wearable devices in clinical trials provide a unique opportunity to monitor behavior in a non-invasive manner. The objective of this study is to identify the correlations between remotely monitored self-reported assessments and objectively measured activities with depression severity assessments often applied in clinical trials. 30 unipolar depressed patients and 29 age- and gender-matched healthy controls were enrolled in this study. Each participant’s daily physiological, physical, and social activity were monitored using a smartphone-based application (CHDR MORE™) for 3 weeks continuously. Self-reported depression anxiety stress scale-21 (DASS-21) and positive and negative affect schedule (PANAS) were administered via smartphone weekly and daily respectively. The structured interview guide for the Hamilton depression scale and inventory of depressive symptomatology–clinical rated (SIGHD-IDSC) was administered in-clinic weekly. Nested cross-validated linear mixed-effects models were used to identify the correlation between the CHDR MORE™ features with the weekly in-clinic SIGHD-IDSC scores. The SIGHD-IDSC regression model demonstrated an explained variance (R 2 ) of 0.80, and a Root Mean Square Error (RMSE) of ± 15 points. The SIGHD-IDSC total scores were positively correlated with the DASS and mean steps-per-minute, and negatively correlated with the travel duration. Unobtrusive, remotely monitored behavior and self-reported outcomes are correlated with depression severity. While these features cannot replace the SIGHD-IDSC for estimating depression severity, it can serve as a complementary approach for assessing depression and drug effects outside the clinic.